Search - Université de Rennes Access content directly

Filter your results

35 Results
authFullName_s : Romain Casey

Comparaison des anti-CD20 et du natalizumab chez des patients avec une SEP très active

Fabien Rollot , Couturier Justine , Romain Casey , Emmanuelle Leray , Sandra Vukusic et al.
Revue Neurologique, 2022, 178 (Suppl.), pp.S111. ⟨10.1016/j.neurol.2022.02.381⟩
Journal articles hal-03820845v1
Image document

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

David-Axel Laplaud , Romain Casey , Laetitia Barbin , Marc Debouverie , Jerome de Sèze et al.
Neurology, 2019, 93 (7), pp.e635-e646. ⟨10.1212/WNL.0000000000007938⟩
Journal articles inserm-02289153v1

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France

Sandra Vukusic , Fabien Rollot , Romain Casey , Julie Pique , Romain Marignier et al.
JAMA neurology, 2020, 77 (1), pp.94. ⟨10.1001/jamaneurol.2019.2670⟩
Journal articles hal-02302155v1

Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis

F. Rollot , Romain Casey , Marc Debouverie , Gilles Edan , S. Wiertlewski et al.
Multiple Sclerosis Journal, 2018, 24, pp.344-345
Journal articles hal-01935071v1

Determinants of Therapeutic Lag in Multiple Sclerosis

Izanne Roos , Emmanuelle Leray , Federico Frascoli , Romain Casey , Dana Horakova et al.
Neurology, 2020, 94 (15)
Journal articles hal-02929410v1

Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

Camille Sabathé , Romain Casey , Sandra Vukusic , Emmanuelle Leray , Guillaume Mathey et al.
Multiple Sclerosis Journal, 2023, 29 (2), pp.236-247. ⟨10.1177/13524585221139156⟩
Journal articles hal-04086418v1
Image document

Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments

Mathilde Lefort , Sandra Vukusic , Romain Casey , Gilles Edan , Emmanuelle Leray et al.
European Journal of Neurology, 2022, 29 (9), pp.2761-2771. ⟨10.1111/ene.15422⟩
Journal articles hal-03690316v1
Image document

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study

Laetitia Barbin , Chloé Rousseau , Natacha Jousset , Romain Casey , Marc Debouverie et al.
Neurology, 2016, 86 (8), pp.771-778. ⟨10.1212/WNL.0000000000002395⟩
Journal articles hal-01299977v1

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal

Fabien Rollot , Justine Couturier , Romain Casey , Sandrine Wiertlewski , Marc Debouverie et al.
Neurotherapeutics, 2022, 19 (2), pp.476-490. ⟨10.1007/s13311-022-01202-1⟩
Journal articles hal-03594074v1
Image document

Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset

Olivier Commowick , Michaël Kain , Romain Casey , Roxana Ameli , Jean-Christophe Ferré et al.
NeuroImage, 2021, 244, pp.1-8. ⟨10.1016/j.neuroimage.2021.118589⟩
Journal articles hal-03358961v1

Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis

Izanne Roos , Emmanuelle Leray , Romain Casey , Dana Horakova , Eva Havrdova et al.
Neurology, 2021, 97 (9), pp.e869-e880. ⟨10.1212/WNL.0000000000012354⟩
Journal articles hal-03282036v1

Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

Antoine Gavoille , Fabien Rollot , Romain Casey , Marc Debouverie , Emmanuelle Le Page et al.
Neurology, 2023, 100 (12), pp.e1296-e1308. ⟨10.1212/WNL.0000000000206774⟩
Journal articles hal-03963580v1

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

Izanne Roos , Charles Malpas , Emmanuelle Leray , Romain Casey , Dana Horakova et al.
Neurology, 2022, 99 (17), pp.e1926-e1944. ⟨10.1212/WNL.0000000000201029⟩
Journal articles hal-03776286v1

Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study

D. A. Laplaud , L. Barbin , Chloé Rousseau , N. Jousset , Romain Casey et al.
Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.62--63
Journal articles hal-01259392v1
Image document

Determinants of Therapeutic Lag in Multiple Sclerosis

Izanne Roos , Emmanuelle Leray , Federico Frascoli , Romain Casey , J William L Brown et al.
Multiple Sclerosis Journal, 2021, 27 (12), pp.1838-1851. ⟨10.1177/1352458520981300⟩
Journal articles hal-03223056v1

Disease-modifying therapies use in primary progressive multiple sclerosis patients in France data from the OFSEP cohort over the 1996-2017 period

Emmanuelle Leray , F. Rollot , Romain Casey , J. de Seze , D. A. Laplaud et al.
Multiple Sclerosis Journal, 2017, 23, pp.659-660. ⟨10.26226/morressier.59a3edacd462b8028d8957a8⟩
Journal articles hal-01716028v1

Identification of Therapeutic Lag in Multiple Sclerosis

Izanne Roos , Emmanuelle Leray , Federico Frascoli , Romain Casey , Dana Horakova et al.
Neurology, 2020, 94 (15)
Journal articles hal-02929403v1

Cumulative effects of therapies on disability in relapsing multiple sclerosis

Fabien Rollot , Romain Casey , Emmanuelle Leray , Marc Debouverie , Gilles Edan et al.
Multiple Sclerosis Journal, 2021, 27 (11), pp.1760-1770. ⟨10.1177/1352458520980366⟩
Journal articles hal-03128421v1

High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag

I. Roos , Emmanuelle Leray , Romain Casey , D. Horakova , E. Kubala Havrdova et al.
Multiple Sclerosis Journal, 2020, 26 (3_SUPPL), pp.534-535
Journal articles hal-03127244v1
Image document

Predictive medicine in multiple sclerosis: A systematic review

Julie Havas , Emmanuelle Leray , Fabien Rollot , Romain Casey , Laure Michel et al.
Multiple Sclerosis and Related Disorders, 2020, 40, pp.101928. ⟨10.1016/j.msard.2020.101928⟩
Journal articles hal-02470973v1
Image document

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament-light chain in multiple sclerosis

Audrey Gauthier , Sébastien Viel , Magali Perret , Guillaume Brocard , Romain Casey et al.
Annals of Clinical and Translational Neurology, 2021, 8 (5), pp.1141-1150. ⟨10.1002/acn3.51355⟩
Journal articles hal-03216866v1

Emulation d’essai clinique randomisé chez des patients atteints d’une sclérose en plaques pour estimer le bénéfice d’un changement de traitement précoce vers un traitement de seconde ligne : approche par scores de propensions dépendant du temps

Camille Sabathé , Romain Casey , Sandra Vukusic , Emmanuelle Leray , David-Axel Laplaud et al.
Epidemiology and Public Health = Revue d'Epidémiologie et de Santé Publique, 2021, 69, pp.S85. ⟨10.1016/j.respe.2021.05.007⟩
Journal articles hal-03820873v1
Image document

The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies

Johanna Andersen , Sifat Sharmin , Mathilde Lefort , Nils Koch-Henriksen , Finn Sellebjerg et al.
Multiple Sclerosis and Related Disorders, 2021, 53, pp.103012. ⟨10.1016/j.msard.2021.103012⟩
Journal articles hal-03268539v1

Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France data from the OFSEP database over the period 1996-2017

Emmanuelle Leray , F. Rollot , Romain Casey , J. de Seze , D. A. Laplaud et al.
Multiple Sclerosis Journal, 2017, 23, pp.709-709. ⟨10.26226/morressier.59a3e8b4d462b8028d894343⟩
Journal articles hal-01716027v1

Quelle utilisation des traitements de fond chez des patients ayant une sclérose en plaques rémittente en France sur la période 1990–2017 ? Étude des données de l’Observatoire français de la SEP

Emmanuelle Leray , Jonathan Roux , F. Rollot , Romain Casey , J. de Seze et al.
Epidemiology and Public Health = Revue d'Epidémiologie et de Santé Publique, 2018, 66, pp.S227. ⟨10.1016/j.respe.2018.04.033⟩
Journal articles hal-02921604v1

Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients' characteristics

Romain Casey , I. El-Bahi , F. Rollot , Francis Guillemin , D. -A. Laplaud et al.
Multiple Sclerosis Journal, 2019, 25 (2_suppl), pp.196-196. ⟨10.1177/1352458519868078⟩
Journal articles hal-02363488v1

Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Izanne Roos , Emmanuelle Leray , Federico Frascoli , Romain Casey , J William L Brown et al.
Brain - A Journal of Neurology , 2020, 143 (9), pp.2742-2756. ⟨10.1093/brain/awaa231⟩
Journal articles hal-02955197v1
Image document

New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions

Stephane Kremer , Salem Hannoun , Fabrice Bonneville , Francoise Durand-Dubief , Thomas Tourdias et al.
Journal de Neuroradiologie / Journal of Neuroradiology, 2020, 47 (4), pp.250-258. ⟨10.1016/j.neurad.2020.01.083⟩
Journal articles hal-02570313v1

Quelle utilisation des traitements de fond chez des patients ayant une SEP rémittente en France sur la période 1990–2017 ? Éléments de réponse à partir des données de l’Ofsep

Emmanuelle Leray , Fabien Rollot , Romain Casey , Jonathan Roux , Jérôme de Seze et al.
Revue Neurologique, 2018, 174, pp.S101. ⟨10.1016/j.neurol.2018.01.228⟩
Journal articles hal-02921615v1

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Sifat Sharmin , Mathilde Lefort , Johanna Balslev Andersen , Emmanuelle Leray , Dana Horakova et al.
CNS Drugs, 2021, 35 (11), pp.1217-1232. ⟨10.1007/s40263-021-00860-7⟩
Journal articles hal-03367246v1